Population Pharmacokinetic‐Pharmacodynamic Analysis of Trastuzumab‐Associated Cardiotoxicity

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical pharmacology and therapy

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/clpt.2011.74PMID 21633346
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

  2010cited by this paper
• Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

  2008cited by this paper
• Diagnosing Model Diagnostics

  2007cited by this paper
• 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

  2007cited by this paper
• Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.

  2007cited by this paper
• Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

  2007cited by this paper
• Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide

  2006cited by this paper
• Randomised controlled trial

  2006cited by this paper
• Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer

  2005cited by this paper
• Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.

  2005cited by this paper
• Congestive heart failure in patients treated with doxorubicin

  2003cited by this paper
• Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™)

  2003cited by this paper
• Cardiac dysfunction in the trastuzumab clinical trials experience.

  2002cited by this paper
• ErbB2 is essential in the prevention of dilated cardiomyopathy

  2002influential reference
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001influential reference
• Role of epirubicin in advanced breast cancer.

  2000cited by this paper
• Three new residual error models for population PK/PD analyses

  1995cited by this paper
• Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development

  1992cited by this paper

• Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients

  2024cites this paper
• Mathematical modeling of cardio-oncology: modeling the systemic effects of cancer therapeutics on the cardiovascular system.

  2023cites this paper
• Precision Cardio-Oncology: Use of Mechanistic Pharmacokinetic and Pharmacodynamic Modeling to Predict Cardiotoxicities of Anti-Cancer Drugs

  2022cites this paper
• A novel cardiovascular systems model to quantify drugs effects on the inter‐relationship between contractility and other hemodynamic variables

  2022cites this paper
• Tolerance and Outcomes of Neoadjuvant Chemotherapy in Geriatric Breast Cancer Patients.

  2022cites this paper
• Monoclonal-induced cardiotoxicity in patients with non-Hodgkin's lymphoma and breast cancer: A retrospective study in an oncology clinic

  2022cites this paper
• Targeted cancer therapies (biologics)

  2019cites this paper
• CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity

  2018cites this paper
• Mathematical modeling of efficacy and safety for anticancer drugs clinical development

  2018cites this paper
• A novel way to manage trastuzumab cardiotoxicity

  2018cites this paper
• Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens

  2018influential citation
• Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer

  2017cites this paper
• Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine.

  2017cites this paper
• Systems pharmacology-based identification of pharmacogenomic determinants of adverse drug reactions using human iPSC-derived cell lines

  2017cites this paper
• Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs

  2017influential citation
• Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment

  2016cites this paper
• Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer

  2016cites this paper
• Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies

  2016cites this paper
• Past, Present, and Future of Antifungal Drug Development

  2016cites this paper
• The Pharmacology, Pharmacokinetics, and Pharmacodynamics of Antibodies

  2016cites this paper
• Clinically-weighted transcriptomic signatures for protein kinase inhibitor associated cardiotoxicity

  2016cites this paper
• Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer

  2016cites this paper
• Antibody Therapeutics in Oncology

  2016cites this paper
• Assessment of Physical Problems Related to Chemotherapy among Patients with Cancer in Al-Najaf City

  2016cites this paper
• S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers

  2015cites this paper
• Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin

  2015cites this paper
• Towards integrative systems pharmacology models in oncology drug development.

  2015cites this paper
• Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

  2015cites this paper
• Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital

  2015cites this paper
• Trastuzumab (herceptin): a retrospective analysis of the effects of long-term application in a series of patients with breast cancer

  2014cites this paper
• Drugs that act on the immune system: cytokines and monoclonal antibodies

  2014cites this paper
• Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.

  2014cites this paper
• I-123-MIBG myocardial imaging in trastuzumab-based cardiotoxicity: the first experience

  2013cites this paper
• Pharmacokinetics and Pharmacodynamics of Peptide and Protein Therapeutics

  2013cites this paper
• Optimizing drug development of anti‐cancer drugs in children using modelling and simulation

  2013cites this paper
• Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.

  2013cites this paper
• Indications et gestion des effets secondaires

  2013cites this paper
• Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer

  2012cites this paper
• Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab

  2012influential citation
• Drugs that act on the immune system

  2011cites this paper